Findings from the first national clinical audit of treatment for people with HIV

HIV Medicine

Volumn 4, Issue 1, 2003, Pages 11-17

  Curtis, Hilary ^a   Sabin, C A ^b   Johnson, M A ^c  

^a British HIV Association   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiretroviral therapy; Clinical audit; Clinical guidelines; United Kingdom

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; HEALTH CARE QUALITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; UNITED KINGDOM; VIRUS LOAD; VIRUS RESISTANCE; ADOLESCENT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HEALTH PERSONNEL ATTITUDE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ATTITUDE OF HEALTH PERSONNEL; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; PRACTICE GUIDELINES; QUESTIONNAIRES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037271310     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00137.x     Document Type: Review

References (21)

1. National Institute of Clinical Excellence, Commission for Health Improvement, Royal College of Nursing, University of Leicester. Principles for Best Practice in Clinical Audit. Oxford, Radcliffe Medical Press, 2002: http://www.nice.org.uk/pdf/BestPractice-ClinicalAudit.pdf.
2. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000; 1: 76-101.
3. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
4. McHenry A, MacDonald N, Sinka K, Mortimer J, Evans B. National assessment of prevalent diagnosed HIV infections. Commun Dis Public Health 2000; 3: 277-281.
5. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309-320.
6. Barry SM, Lloyd-Owen SJ, Madge SJ et al. The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Med 2002; 3: 129-134.
7. Easterbrook PJ, Yu LM, Goetghebeur E, Boag F, McLean K, Gazzard B. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic. AIDS 2000; 14: 561-571.
8. Gupta SB, Gilbert RL, Brady AR, Livingstone SJ, Evans BG. CD4 cell counts in adults with newly diagnosed HIV infection: results of surveillance in England and Wales, 1990-1998. CD4 Surveillance Scheme Advisory Group. AIDS 2000; 14: 853-861.
9. Saul J, Erwin J, Bruce JC, Peters B. Ethnic and demographic variations in HIV/AIDS presentation at two London referral centres, 1995-9. Sex Transm Infect 2000; 76: 215.
10. Department of Health. Better Prevention, Better Services, Better Sexual Health: the National Strategy for Sexual Health and HIV. London, Department of Health, 2001: http://www.doh.gov.uk/nshs.
11. Eyster E, Jemsek J, Kagan S et al. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, SUSTIVA™, DMP 266) in antiretroviral therapy naïve or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II open-label, multicenter study at 24 weeks (Study DMP 266-024). 12th World AIDS Conference. Geneva, Switzerland, June-July 1998 [Abstract 22386].
12. Gisolf EH, Jurriaans S, Pelgrom J et al. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000; 14: 405-413.
13. Stephan CJ, Lutz T, Kurowski M, Gute P, Staszewski S. Lopinavir/ritonavir versus ritonavir boosted saquinavir plasma levels. Abstract TuPeB4561. 14th International AIDS Conference. Barcelona, Spain, July 2002 [abstract TuPeB4561].
14. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-868.
15. Staszewski S, Miller V, Sabin C et al. VIrological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13: 367-373.
16. Grabar S, Pradier C, Le Corfec E et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-149.
17. Paredes R, Mocroft A, Kirk O et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Int Med 2000; 160: 1123-1132.
18. Phillips AN, Staszewski S, Weber R et al. HIV Viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-2567.
19. Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-29.
20. Matthews GV, Sabin CA, Mandalia S et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16: 53-61.
21. Murphy GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Int Med 1999; 131: 81-87.